Eversheds says Sun Pharmaceuticals deal represents opportunity in generics market

Eversheds partner Richard Lewis has commented on Sun Pharmaceuticals’ acquisition of Ranbaxy.

Lewis said: ‘This deal is a clear sign of further consolidation in the Indian generics market as companies look to increase market share, enhance growth opportunities and reduce costs.

‘As the country’s largest pharma company, it will now be particularly well placed to capitalise on the fast-growing Indian pharmaceuticals market.’

  • Print

Briefings from Eversheds

View more briefings from Eversheds

Analysis from The Lawyer

View more analysis from The Lawyer

Overview

1 Wood Street
London
EC2V 7WS
UK
http://www.eversheds.com

Turnover (£m): 376.00
No. of lawyers: 1,264
Jurisdiction: UK
No. of offices: 4
No. of qualified lawyers (international): 54